Climb Bio Reports Positive Initial Phase 1 Safety Data for CLYM116, Advancing to Phase 2
CLYM has more than doubled off its 52-week low of $1.16.
Summary
Climb Bio reported positive initial Phase 1 safety data for CLYM116, indicating good tolerability and paving the way for Phase 2 studies in IgAN patients by Q3 2026.
Key Events · Product Development and Regulatory · CLYM
-
Positive Phase 1 Safety Data
CLYM116 was generally well tolerated in healthy volunteers receiving single doses up to 320 mg, with no serious adverse events or dose-limiting toxicities reported.
-
Translational Modeling Results
Pharmacometric modeling projected healthy human exposure and dose-dependent IgA suppression for CLYM116, suggesting potential for less-frequent dosing.
-
Advancement to Phase 2
The company plans to continue clinical development for CLYM116, and its partner Mabworks expects to initiate Phase 2 dosing in IgAN patients in Q3 2026.
Analysis · CLYM · Life Sciences
Climb Bio announced positive initial Phase 1 safety data for its drug candidate CLYM116, showing it was generally well tolerated with no serious adverse events. This data, combined with translational modeling, supports advancing CLYM116 into further clinical development, with its partner Mabworks planning to initiate Phase 2 dosing in IgAN patients in Q3 2026. This progress is important for the company's pipeline and future growth.
At the time of this filing, CLYM was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $624.7M. The 52-week trading range was $1.16 to $12.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.